Monsanton käyttäytyminen?

[Heikki Jokipii]

Australiassa näillä kanteen nostajilla ei mennytkään niinkuin Ströms... ei kun USA:ssa:

Australian glyphosate class action suit with 20,000 plaintiffs dismissed, judge says evidence supporting cancer claims lacking

[Heikki Jokipii]

Tähän följetongiin uusi luku:

Will the Supreme Court block further glyphosate suits against Bayer?

Globally, Bayer is focusing on securing a favorable ruling by the U.S. Supreme Court on the federal pre-emption question, which could largely end the RoundUp litigation.  As far as Bayer is concerned, from the scientific point of view, out of the 16 epidemiological studies, there is no consistent or reliable proof that RoundUp causes cancer.

[Heikki Jokipii]

Australiasta vielä:

‘No link found between cancer and glyphosate’: Australian federal court voids all outstanding glyphosate cancer claims

McNickle was the first Roundupâ,,¢ final judgment outside of the United States on the question of whether glyphosate, the active ingredient in Roundupâ,,¢, causes non-Hodgkin lymphoma (NHL). The Court issued a 322-page ruling finding that the weight of scientific evidence does not support a link between glyphosate and NHL. This is an outcome consistent with worldwide regulatory and scientific assessments, including from the Australian Pesticides and Veterinary Medicines Authority (APVMA), concluding that glyphosate is not carcinogenic.

In the United States, Bayer will continue its multipronged strategy to significantly contain the Roundupâ,,¢ litigation. Having achieved favorable outcomes in 15 of the last 22 trials, the company has a winning record in court and will continue to try cases, based on the overwhelming scientific and regulatory evidence in support of the safety of glyphosate. Additionally, the company will seek U.S. Supreme Court review on the cross-cutting question of whether all of the state-based warning claims in this litigation are preempted by federal law, and is currently evaluating cases to determine the best vehicle for this appeal. In the meantime, Bayer will consider settlements if they are in the company’s interest and also continuously evaluate any other possible means to contain the legal risks.